Capricor Therapeutics (NASDAQ:CAPR) Shares Down 7% – Time to Sell?

Capricor Therapeutics Inc (NASDAQ:CAPR) traded down 7% on Wednesday . The stock traded as low as $17.46 and last traded at $17.98. 1,433,298 shares were traded during trading, an increase of 38% from the average session volume of 1,039,810 shares. The stock had previously closed at $19.33.

Analysts Set New Price Targets

CAPR has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price objective on shares of Capricor Therapeutics in a research report on Friday, September 20th. Maxim Group boosted their price target on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a report on Wednesday. Finally, Oppenheimer reissued an “outperform” rating and set a $15.00 target price on shares of Capricor Therapeutics in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Capricor Therapeutics Trading Down 1.0 %

The firm’s fifty day simple moving average is $7.16 and its 200-day simple moving average is $6.00.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The firm had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. On average, sell-side analysts forecast that Capricor Therapeutics Inc will post -1.13 earnings per share for the current year.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The stock was acquired at an average price of $5.36 per share, with a total value of $14,999,997.52. Following the completion of the purchase, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 12.00% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of Capricor Therapeutics by 17.2% during the 1st quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock valued at $9,274,000 after acquiring an additional 200,499 shares during the period. Marshall Wace LLP acquired a new position in shares of Capricor Therapeutics during the second quarter valued at about $426,000. Renaissance Technologies LLC boosted its position in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after purchasing an additional 84,350 shares in the last quarter. Rhumbline Advisers bought a new position in shares of Capricor Therapeutics during the 2nd quarter worth about $147,000. Finally, Bank of New York Mellon Corp increased its position in Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after buying an additional 9,040 shares in the last quarter. 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.